Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes by Schroth Werner, Antoniadou Lydia, Fritz Peter, Schwab Matthias, Muerdter Thomas, Zanger Ulrich M, Simon Wolfgang, Eichelbaum Michel, Brauch Hiltrud in Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007).

[PMID: 18024866] PubMed


The clinical outcome of tamoxifen-treated breast cancer patients may be influenced by the activity of cytochrome P450 enzymes that catalyze the formation of antiestrogenic metabolites endoxifen and 4-hydroxytamoxifen. We investigated the predictive value of genetic variants of CYP2D6, CYP2C19, and three other cytochrome P450 enzymes for tamoxifen treatment outcome.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Dosing Information

No dosing information annotated.